The results are in from Eli Lilly's latest Phase lll study of Solanezumab as a neuroprotector for patients with Alzheimer's disease. The trial results were disappointing but the drug shouldn't be written off just yet, according to the company.
The latest trial of Solanezumab, a monoclonal antibody, didn't meet its endpoints, but Lilly CEO John Lechleiter said the pooled data appears to demonstrate that the drug slows cognitive decline by a statistically significant amount in sub-groups of patients with mild, or mild to moderate Alzheimer's.
Lilly plans to share the pooled data with the FDA and discuss "next steps," according to Lechleiter's statement.
The company says another arm of the trial, called EXPEDITION-EXT, an open-label extension safety study, will continue.
Comments